March 28 (Reuters) - Tricida Inc TCDA.O :
* TRICIDA ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018
FINANCIAL
RESULTS
* Q4 LOSS PER SHARE $0.66
* INITIAL TOPLINE DATA ANALYSES OF TRCA-301E TRIAL,
PLACEBO-CONTROLLED, BLINDED, 40-WEEK EXTENSION TRIAL, REVEALED
POSITIVE RESULTS
* AMENDMENT TO ITS EXISTING DEBT FACILITY WITH HERCULES
CAPITAL,
INC., INCREASING TOTAL AMOUNT AVAILABLE UNDER DEBT FACILITY TO
UP TO $200 MILLION
* TRCA-301E TRIAL MET ITS PRIMARY AND ALL SECONDARY
ENDPOINTS
* ESTIMATES A CASH EXPENDITURE OF $135 TO $145 MILLION IN
2019
* AS OF DECEMBER 31, 2018, CASH, CASH EQUIVALENTS AND
INVESTMENTS
WERE $243.4 MILLION
Source text for Eikon: ID:nBw2kYWZJa
Further company coverage: TCDA.O
((Reuters.Briefs@thomsonreuters.com;))